Home Podcasts Uncapped: Stories from the Grey Market
Uncapped: Stories from the Grey Market

Uncapped: Stories from the Grey Market

krysia 65 Episodes May 3, 2026

Uncapped explores the underground grey market for peptides, research compounds, and the Discord and Telegram communities that operate around it. Each episode combines real events—from chaotic group buys to vendor takedowns—with educational breakdowns, industry interviews, and commentary from people involved in the unregulated trade. The show examines what happens behind the scenes of so-called trusted vendors and how these informal markets function.

Episodes

Copyright claims. Trademark threats. Tacky 3D keychains.
Copyright claims. Trademark threats. Tacky 3D keychains. May 3, 2026 00:06:36 Just normal life in this crazy grey market communityIn this episode, I look at another ridiculous corner of the grey market community, where public kit photos can suddenly become a copyright issue, and a petty trademark attempt over the name K-Hole somehow becomes part of the drama.From the JEEP T30 fallout to a completely separate attempt to claim ownership over my server name, K -Hole, this one
Krysia's FREE Guide to "Going Grey"
Krysia's FREE Guide to "Going Grey" May 2, 2026 00:09:10 A practical guide to navigating vendors, risk, and uncertainty for those new to this worldThis guide is for anyone trying to crack the grey market for the first time. It’s what I would do if I were starting out now, knowing everything I know today.This episode covers the basics: what to do after joining my servers, how to start reading the market, and how to find a vendor for your very first order
CGMP claims in the RUO Peptide Space
CGMP claims in the RUO Peptide Space Apr 30, 2026 00:23:13 This episode breaks down what GMP and cGMP actually mean, and why broad cGMP claims on RUO peptide websites should be treated with scepticism.GMP and cGMP are strict quality systems overseen by regulators such as the FDA. They require traceability, documented processes, controlled environments, QA oversight, and inspection. If those controls are missing, the GMP claim falls apart.A major grey-mark
The Phoenix Group Buy Scam; Part 1
The Phoenix Group Buy Scam; Part 1 Apr 6, 2026 00:10:03 How “seized shipments” turn into second profits and why the same buyers may pay twiceScams are nothing new in the grey market.But this one works a little differently.In this episode, we break down what’s being described as the “Phoenix group buy scam” a pattern where a failed or allegedly failed group buy may not be the end of the story.Instead, it can become the starting point for something else.
Friendship in the Grey Zone; Useful until you're not
Friendship in the Grey Zone; Useful until you're not Mar 28, 2026 00:05:25 This episode explores a side of the grey zone that isn’t talked about enough.Not the peptides. Not the vendors. Not the scams.But the people.Inside tight-knit communities, friendship often comes with conditions. You’re valuable while you’re useful. But when that changes, so does the relationship.From gossip, alt accounts, back stabbing and surveillance… to something more personal, the emotional wh
Just another day in the Grey Zone
Just another day in the Grey Zone Mar 25, 2026 00:07:24 Scams, impersonators, vendor disputes, disappearing chats, and a collaboration offer I definitely wasn’t expecting.This episode is a real-time look at what one day in the grey zone actually looks like for me, narrated in my own voice.
Vial vs body; Tirzepatide + vitamin B12
Vial vs body; Tirzepatide + vitamin B12 Mar 22, 2026 00:19:55 What really happens when tirzepatide and vitamin B12 are mixed in the same vial?In this deep dive, we break down the science behind Eli Lilly’s recent warning and preprint, which identified a previously unknown tirzepatide–B12 molecular complex in compounded samples, in some cases making up a significant portion of the vial. The analysis also revealed major potency variation, with some products te
Eli Lilly's Tirzepatide and B12 warning;
Eli Lilly's Tirzepatide and B12 warning; Mar 20, 2026 00:20:43 What their data shows and what it still doesn't explain.What happens when a blockbuster drug meets a common vitamin?In this deep dive, we unpack Eli Lilly’s warning about tirzepatide mixed with vitamin B12, and the science behind the controversy.A newly released preprint shows that when the two are combined, they can form a previously unknown molecular complex, detected in real world samples. Some
The NAD Testing Paradox
The NAD Testing Paradox Mar 16, 2026 00:09:35 Why do some labs report 99%+ purity for NAD, while others refuse to give a purity number at all?This episode unpacks what is known as the NAD Testing Paradox.NAD is often analysed using methods designed for peptides, but chemically it behaves very differently. Because NAD naturally breaks down into related molecules like nicotinamide, ADP-ribose, AMP and ADP, purity numbers can sometimes reflect t
What comes after RUO?
What comes after RUO? Mar 15, 2026 00:19:24 How Telehealth, US Manufacturing and 503A Ambitions are Rebuilding the Peptide MarketThe peptide market may be moving into a new phase.For years, much of the industry operated through Research Use Only (RUO) websites selling peptides in a legal grey zone. But that model is coming under pressure from payment processors, regulators, and changing mrket expectations.This episode explores what may be r
The Real Pressure Behind the end of RUO; The Payment Processors
The Real Pressure Behind the end of RUO; The Payment Processors Mar 14, 2026 00:23:08 For years the grey-market peptide ecosystem operated in a strange legal balance. Products were sold under “Research Use Only” labels while being widely discussed in wellness communities, clinics, and online forums. Regulators knew the contradiction existed, but the system continued to function.So what is actually destabilising the RUO model now?In this episode we look at a factor that rarely gets
From RUO to PUO; How the peptide industry is relabelling the same supply model
From RUO to PUO; How the peptide industry is relabelling the same supply model Mar 14, 2026 00:19:25 In this episode we unpack the shift from Research Use Only (RUO) peptides to the emerging Physician Use Only (PUO) label.At first glance, PUO might look like a move toward a more legitimate, physician-driven distribution model. But a closer look suggests something more complex.PUO is not an FDA regulatory category and does not automatically place peptides inside licensed pharmacy frameworks such a

Recommended